CONCUSS Randomised Clinical Trial of Vergence/Accommodative Therapy for Concussion-Related Symptomatic Convergence Insufficiency

Why It Matters

Early OBVAM shortens symptom duration and accelerates return to academic or athletic activities, offering a proven, dose‑responsive treatment for concussion‑related visual deficits.

Key Takeaways

• Immediate OBVAM yields 88% success versus 8% delayed
• NPC improved by 7.9 cm vs 1.8 cm after six weeks
• PFV increased 17.5 points in immediate group, 2.5 delayed
• Symptom scores improved for 79% immediate, 13% delayed participants
• Full 16 sessions equalize outcomes, confirming dose‑response effect

Pulse Analysis

Concussion‑related convergence insufficiency (CONC‑CI) affects a sizable subset of adolescents and young adults recovering from mild traumatic brain injury. The condition manifests as difficulty maintaining near focus, leading to headaches, eye strain, and reduced academic or athletic performance. Traditional management has relied on symptom monitoring and gradual visual rehabilitation, but evidence for specific therapeutic protocols has been limited. As schools and sports programs demand faster return‑to‑play timelines, clinicians have sought interventions that can accelerate visual recovery without compromising safety.

The CONCUSS randomized trial provides robust data on office‑based vergence/accommodative therapy with movement (OBVAM). Participants receiving immediate OBVAM achieved an 88 % success rate on composite near point of convergence (NPC) and positive fusional vergence (PFV) measures, compared with only 8 % in the delayed arm after six weeks. Objective improvements included a 7.9 cm reduction in NPC and a 17.5‑point gain in PFV, translating into a 79 % symptom‑score response on the CISS. A dose‑response pattern emerged, with success climbing from 88 % after 12 sessions to 94 % after the full 16‑session regimen, after which delayed participants caught up, confirming the therapy’s efficacy rather than a timing artifact.

For eye‑care professionals and concussion specialists, these findings endorse early initiation of OBVAM as a standard component of post‑concussion care pathways. Shortening the symptomatic window can reduce academic downtime, lower healthcare utilization, and support quicker clearance for sports participation. The trial also highlights the importance of structured, twice‑weekly dosing, suggesting that insurance reimbursement models should accommodate this schedule. Future research may explore tele‑health delivery, integration with vestibular therapy, and long‑term durability of gains, positioning OBVAM as a cornerstone in multidisciplinary concussion management.